Quince Therapeutics, Inc. financial data

Symbol
QNCX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
611 Gateway Blvd., Suite 273, South San Francisco, CA
State of incorporation
California
Fiscal year end
December 31
Former names
Cortexyme, Inc. (to 8/1/2022)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 927 % -67.5%
Debt-to-equity 89.2 % +2401%
Return On Equity -73.4 % -129%
Return On Assets -38.8 % -25.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.3M shares +18.9%
Common Stock, Shares, Outstanding 43.3M shares +19.1%
Entity Public Float 50M USD -28.6%
Common Stock, Value, Issued 43K USD +19.4%
Weighted Average Number of Shares Outstanding, Basic 43.1M shares +20%
Weighted Average Number of Shares Outstanding, Diluted 43.1M shares +20%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12.7M USD +29.7%
General and Administrative Expense 19.3M USD +21.4%
Operating Income (Loss) -55.5M USD -71.1%
Income Tax Expense (Benefit) 512K USD
Net Income (Loss) Attributable to Parent -53.1M USD -73.6%
Earnings Per Share, Basic -1.26 USD/shares -59.5%
Earnings Per Share, Diluted -1.26 USD/shares -59.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.8M USD -3.49%
Cash, Cash Equivalents, and Short-term Investments 59.4M USD -32.2%
Other Assets, Current 79K USD -44.8%
Assets, Current 63.4M USD -28.4%
Property, Plant and Equipment, Net 246K USD +4000%
Operating Lease, Right-of-Use Asset 554K USD +404%
Intangible Assets, Net (Excluding Goodwill) 61.8M USD
Goodwill 0 USD
Other Assets, Noncurrent 8.8M USD
Assets 135M USD +51.8%
Accounts Payable, Current 2.41M USD +581%
Accrued Liabilities, Current 2.92M USD +82.4%
Liabilities, Current 10.3M USD +429%
Deferred Income Tax Liabilities, Net 5.17M USD
Operating Lease, Liability, Noncurrent 453K USD
Other Liabilities, Noncurrent 609K USD
Liabilities 87.9M USD +4401%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.09M USD +323%
Retained Earnings (Accumulated Deficit) -359M USD -17.4%
Stockholders' Equity Attributable to Parent 47M USD -45.9%
Liabilities and Equity 135M USD +51.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.35M USD -134%
Net Cash Provided by (Used in) Financing Activities 190K USD +280%
Net Cash Provided by (Used in) Investing Activities 8.91M USD +60.9%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 43.3M shares +19.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.06M USD -50.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.89M USD -65.2%
Deferred Tax Assets, Valuation Allowance 85.1M USD +22.1%
Deferred Tax Assets, Gross 97.4M USD +37.7%
Operating Lease, Liability 547K USD +272%
Payments to Acquire Property, Plant, and Equipment 39K USD -71.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -52.3M USD -75.1%
Lessee, Operating Lease, Liability, to be Paid 667K USD +348%
Operating Lease, Liability, Current 94K USD -36.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 133K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 136K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +47.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 120K USD +5900%
Lessee, Operating Lease, Liability, to be Paid, Year Three 127K USD
Deferred Tax Assets, Operating Loss Carryforwards 81.9M USD +65.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.34M USD +17.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 203K USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 12.3M USD +1089%
Share-based Payment Arrangement, Expense 1.02M USD +1123%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%